Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that it has entered into convertible note and loan financing facilities for up to $48.5 million with affiliates of Marathon Asset Management L.P. (Marathon) and SWK Holdings Corporation (Nasdaq: SWKH), subject to certain conditions. Proceeds from these financings would be used to advance Acer’s pipeline.
This author has not written his bio yet.
But we are proud to say that reedland contributed 67 entries already.
Entries by reedland
Agreement aims to accelerate development of a unique testosterone treatment for inflammatory breast diseases and estrogen-receptor positive breast cancer
Reedland Capital Partners Corporate Debt Advisory Group Expands with Senior Hire
Chicago, IL – December 20, 2018 – Encina Business Credit, LLC (EBC) announced today that it has provided a $60 million senior secured credit facility to a provider of waste management solutions. The credit facility consists of a revolver secured by accounts receivable, the proceeds of which are being used to refinance the company’s existing […]